{"id":"W2754917529","doi":"10.1007/s00125-017-4430-0","title":"Bladder cancer in the EMPA-REG OUTCOME trial","year":2017,"lang":"en","type":"letter","venue":"Diabetologia","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto","funders":"Novo Nordisk; Intarcia Therapeutics; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"EMPA; Empagliflozin; Human physiology; Medicine; Cancer; Diabetes mellitus; Internal medicine; Bladder cancer; Oncology; Type 2 diabetes; Endocrinology; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005395798,0.0006388437,0.001596834,0.000458529,0.001189819,0.002020567,0.001492348,0.01413837,0.005704977],"category_scores_gemma":[0.03096526,0.0004309628,0.0009841636,0.0006484832,0.0008674299,0.001621502,0.0007354691,0.01438862,0.003581967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002275746,"about_ca_system_score_gemma":0.002649707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00140421,"about_ca_topic_score_gemma":0.003147183,"domain_scores_codex":[0.9953689,0.002620802,0.0004478662,0.000357286,0.0008498431,0.0003553196],"domain_scores_gemma":[0.9893249,0.006709774,0.00107304,0.0001734727,0.001560627,0.001158319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.0008466762,0.00006190827,0.001653711,0.0003203018,0.0001179281,0.0008550021,0.0000487966,0.00009447441,0.000101886,0.000574324,0.9794832,0.01584175],"study_design_scores_gemma":[0.006028769,0.001038197,0.01401315,0.003523603,0.0009683099,0.004069302,0.000420799,0.002552605,0.001052253,0.008192969,0.9579233,0.0002167307],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.001680509,0.006610801,0.00006035832,0.9637014,0.02444657,0.00002979934,0.0004900733,0.00003207777,0.002948424],"genre_scores_gemma":[0.01806486,0.004873996,0.0001660062,0.8693704,0.1012417,0.000176773,0.0002960259,0.0000387808,0.005771502],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01413837,"threshold_uncertainty_score":0.02853608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07815138698429328,"score_gpt":0.3762121577773796,"score_spread":0.2980607707930863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}